The mammalian Runx gene family (Runx1-3) are transcription factors that play essential, lineage-specific roles in development. A growing body of evidence implicates these genes as mutational targets in cancer where, in different contexts, individual family members have been reported to act as tumour suppressors, dominant oncogenes or mediators of metastasis. We are exploring these paradoxical observations by ectopic expression of RUNX genes in primary murine embryonic fibroblasts where, in common with a number of other dominant oncogenes, RUNX1 induces senescence-like growth arrest in the presence of an intact p19 ARF -p53 pathway. We now report that, in MEFs lacking functional p53, RUNX1 has apparently prooncogenic effects on cell growth that include cytoskeletal reorganization, reduced contact inhibition at confluence and accelerated tumour expansion in vivo. On the other hand, RUNX1 conferred no obvious growth advantage at low cell density and actually delayed entry of primary MEFs into S phase. We also found that ectopic RUNX1 interferes with the morphological and growth responses of p53-null MEFs to TGFb indicating that these effects are mediated by overlapping pathways. These observations help to elucidate the context-dependent consequences of loss and gain of Runx activity.
Introduction
The mammalian Runx genes have been widely implicated in cancer development. Paradoxically, evidence exists for their involvement both as dominant oncogenes and as tumour suppressor genes, albeit in different lineage and cellular contexts (Speck and Gilliland, 2002) . The oncogenic role of RUNX1 is revealed in human leukaemias where the gene is often disrupted by chromosomal translocations that generate oncogenic fusion products (Frank et al., 1995; Meyers et al., 1995) , and by its amplification and over-expression in cases of ALL (Niini et al., 2000; Dal Cin et al., 2001; Mikhail et al., 2002; Harewood et al., 2003) . Loss of function of RUNX1 is implicated in human myeloid leukaemias, where biallelic somatic mutations have been observed (Preudhomme et al., 2000) , and RUNX1 haploinsufficiency underlies the inherited leukaemia predisposition syndrome, familial platelet disorder (Song et al., 1999) . Moreover, the oncogenic fusion proteins generated by the common chromosomal translocations such as RUNX1-ETO appear to act as dominant-negative inhibitors with respect to the normal gene (Yergeau et al., 1997; Okuda et al., 1998) , suggesting that loss of RUNX1 function is a key event in these cases. RUNX3 also seems to act as a tumour suppressor in human gastric cancers where the gene is subject to hypermethylation or point mutation (Li et al., 2002) . Inactivation of murine Runx3 is synergistic with p53 loss in murine epithelial hyperplasia and gastric cancer (Li et al., 2002) . Finally, studies in our own and other laboratories have shown that all three murine Runx genes can act as targets for retroviral activation in T-cell lymphomas (Stewart et al., 1997 Li et al., 1999; Wotton et al., 2002) , and demonstrate that Runx1 does not operate as a tumour suppressor in this lineage (Wotton et al., 2002) .
Further evidence of the dualistic effects of Runx gene expression come from transgenic mouse studies where ectopic expression of Runx2 predisposes to lymphoma development and is potently synergistic with other oncogenes such as Myc, Myb and Pim-1, and with germ-line inactivation of p53 Cameron et al., 2003) . Examination of preleukaemic Runx2 transgenic mice showed that the primary effect of ectopic Runx2 expression is actually inhibition of normal growth and development . A corollary of this observation is that mutations to cooperating genes must be required to release the observed Runx2-induced block to proliferation in vivo. We also found that ectopic Runx2 in nontransformed T lymphocytes amplified the growth inhibitory effects caused by the addition of exogenous TGFb, suggesting that Runx2 may be acting on the same pathway (Vaillant et al., 1999) . Consistent with this hypothesis, a growing body of evidence shows that a number of important biological responses are coregulated by Runx and TGFb/BMP signalling (Jakubowiak et al., 2000; Bae et al., 2001; Ito and Miyazono, 2003) and, like the effects of TGFb itself, are likely to be highly dependent on the cellular context. Given the established role of TGFb in cellular transformation and metastasis, it is intriguing that RUNX2 can act as an inducer of motility and promote invasiveness in endothelial cells (Sun et al., 2001) . Although the role of RUNX2 in human cancer remains an enigma, its expression in tumour metastases homing to bone appears to be inconsistent with an exclusively tumour suppressor role (Yeung et al., 2002; Brubaker et al., 2003) .
With the aim of establishing a system to examine the context-dependent effects of Runx deregulation, we examined the consequences of ectopic Runx in primary murine fibroblasts. These studies were conducted using RUNX1, as this gene has previously been the subject of conflicting reports on its ability to transform murine 3T3 fibroblasts (Kurokawa et al., 1996; Frank et al., 1999) , while the available tools included a regulatable form of RUNX1 which can be functionally induced in vitro (Lou et al., 2000) . This work confirms the ability of RUNX1 to induce cell transformation and promote tumour development in vivo. The transformed phenotype was manifested only at high cell densities and could only be studied in p53-null cells, as expression of RUNX1 led rapidly to growth arrest and stasis in wild-type MEFs.
Results

Senescence-like growth arrest of MEFs is mediated by wild-type and repressive forms of RUNX1
It has been recently reported that RUNX1 induces senescence-like growth arrest in primary MEFs, and that this effect is spared in cells lacking expression of p19 ARF , an inducer of the p53 pathway (Linggi et al., 2002) . Since this phenomenon hindered our aim to establish a permissive system in which to explore the growth regulatory effects of RUNX1 in primary cells, we tested instead a 4-hydroxytamoxifen (4-OHT)-inducible RUNX1 construct (RUNX1-ER), which comprises the full-length P2 (MRIPV) isoform of RUNX1 fused to a mutated oestrogen receptor (Littlewood et al., 1995; Lou et al., 2000) . We found that RUNX1-ER was also a potent inducer of senescencelike growth arrest, with cells displaying the characteristic features of a flattened morphology and expression of endogenous b-galactosidase (Figure 1a, d) . Interestingly, this effect was seen both in the presence and absence of inducer, suggesting that either the effect was being mediated by protein-protein interactions or that leakiness in the system was sufficient to induce the phenotype. Despite the observation that 4-OHT treatment results in a marked shift of RUNX1-ER from the cytoplasm to the nucleus, it is clear that some RUNX1-ER protein is present in the nucleus even in the absence of treatment (Figure 1b) . However, 4-OHT treatment tightly regulates a gel mobility shift, presumably due to post-translational modification of the RUNX1-ER product ( Figure 1b and data not shown).
We explored this phenomenon further by using a construct consisting of a KRAB transcriptional repressor domain linked to the runt DNA-binding domain of RUNX1 and the inducible modified ER domain (KRAB-RUNX1-ER). The linkage of the KRAB repressor domain to the runt homology domain of RUNX1 should result in constitutive repressor activity (Margolin et al., 1994; Lou et al., 2000) . This construct also induced senescence-like growth arrest in the RUNX1 increases growth saturation density in p53-null MEFs, while a repressor construct suppresses growth
Genetic evidence has implicated the p19 ARF -p53 pathway in the growth inhibition following RUNX1 expression in wild-type MEFs (Linggi et al., 2002) . We therefore tested the effects of the same constructs in primary MEFs established from p53-null mice and found that in these cells, RUNX1-ER was not growth inhibitory. On the contrary, 4-OHT-treated RUNX1-ER cells grew to significantly greater densities than cells containing the empty vector (Puro-control) by day 8 of culture ( Figure 2a ). Whereas the number of viable cells in the Puro-control culture reached a plateau, induced RUNX1-ER cells continued to accumulate slowly (data not shown and Figure 2b ). Unlike the situation in wildtype MEFs, this effect was fully inducible and significantly increased cell density was not observed in untreated RUNX1-ER cells. This high-density growth did not appear to be due to genetic instability mediated by lack of functional p53, as it was reproduced precisely in four separate experiments using freshly transduced low-passage p53-null MEFs. To eliminate the possibility that the ER domain itself was exerting a spurious gain of function, p53-null MEFs were transduced with a RUNX1 construct containing the same P2 isoform of RUNX1 but lacking the ER domain (Linggi et al., 2002) . Cultures containing the wild-type RUNX1 also grew to significantly (P ¼ 0.01) higher densities than those carrying the control vector. In contrast to the results with RUNX1 and RUNX1-ER, 4-OHT-treated cells expressing the KRAB-RUNX1-ER vector had a significantly reduced cell density compared to control cells (Po0.01) (Figure 2b ). These results show that the repressive growth effects of the KRAB-RUNX fusion protein operate independently of the p53 pathway and implicate the transcriptional activation potential of RUNX1 in the increased growth density of p53-null MEFs.
Primary MEF cultures represent a relatively heterogeneous population of cells in terms of morphology and differentiation potential. To examine the effects of RUNX1 on a more uniform background, a series of clones expressing RUNX1-ER or the control vector were derived from single MEF cells. In total, eight RUNX1-ER and seven vector control clones were isolated. During clonal expansion two of the RUNX1-ER clones lost the ability to respond to 4-OHT but the remaining six clones retained 4-OHT sensitivity, and, despite a degree of clone-to-clone variation, the individual clones displayed stable growth characteristics over a number of passages. As in the bulk cultures there was no significant difference in the growth of 4-OHTtreated or untreated cells during early stages of culture. However, as cells reached confluence, treated cells showed a significant growth advantage (Po0.01) in all six clones. 4-OHT treatment did not affect the growth of any of the seven Puro-control clones. Representative growth curves are shown in Figure 2c -f. These data confirmed that RUNX1-expressing cells could grow to significantly higher densities and show that enhanced growth potential is a stable, heritable property of individual RUNX1-expressing cells.
RUNX1-expressing MEFs can be induced to form transformed foci but retain responsiveness to contact inhibitory growth signals from normal cells
To test the ability of RUNX1 to reactivate growth in contact inhibited cells, p53-null MEFs transduced with RUNX1-ER were grown for 10 days until they reached confluence, when 4-OHT was added to the cultures to induce RUNX1 activity. 4-OHT treatment of RUNX1-ER p53-null MEFs consistently resulted in the appearance of large numbers of transformation foci (Figure 3a) . The appearance of such foci was not observed in untreated RUNX1-ER cells ( Figure 3b ) nor in Purocontrol cells (data not shown). Focus formation was also observed in 4-OHT-treated RUNX1-ER clones but not in Puro-control clones. Furthermore, these results were repeated using the constitutive RUNX1 construct confirming that this effect is independent of the ER domain.
Together, these results demonstrate that in addition to decreased sensitivity to contact-dependent growth inhibition, RUNX1 is capable of inducing a transformed phenotype characterized by focal accumulations and multilayered cell growth.
To investigate the nature of this apparent loss of contact inhibition, we followed a method previously used to demonstrate transformation suppression by normal bystander cells (Sakamoto et al., 1999; Nelson and Daniel, 2002) . Cells from a RUNX1-ER-expressing clone (AE4) were cultured together with cells from a Puro-control clone (PE4) in a 50 : 50 ratio. In agreement with previous experiments, 4-OHT treatment resulted in a significant increase in RUNX1-ER cells at day 14 of culture. However, this effect was completely abolished when RUNX1-ER cells were cocultured with Purocontrol cells (Figure 4 ). This result was reproducible using two other combinations of RUNX1-ER-expressing and Puro-control clones. Furthermore, suppression appears to require cell-cell contact as neither conditioned medium nor co-culture in chambers preventing direct cell contact resulted in inhibition of RUNX1-induced high-density growth (data not shown). These results are consistent with the notion that RUNX1-ER cells retain the capacity to respond to growth inhibitory signals but have lost the capacity to deliver such signals to neighbouring cells.
RUNX1-ER cells exhibit delayed entry into S phase
Despite the increased saturation density of RUNX1-expressing cells, no growth advantage was observed during the early phase of culture. Indeed at early stages, a small but consistent reduction in cell count in 4-OHTtreated RUNX1-ER cells was frequently observed (not shown). To clarify the effect of RUNX1 on the MEF cell cycle, RUNX1-ER cells were synchronized by serum starvation and cell cycle progression was analysed following return to medium containing 10% serum.
Two RUNX1-ER representative clones (AE4 and AE2) and one control vector clone (PE4) were selected for this study. Profound differences were observed in the cell cycle profiles of 4-OHT-treated RUNX1-ER cells 18 h after synchronization. In both RUNX1-ER clones, 4-OHT treatment resulted in significantly (Po0.01) fewer cells entering S phase during this time period ( Figure 5 ). By contrast, there was no difference in the proportion of cells entering S phase between the treated or untreated Puro-control cells at any time point. These findings indicate that the RUNX1-induced increase in cell number is due to a failure of contact inhibition at high cell density rather than a shortened G1 phase or an increase in the proportion of RUNX1-ER cells entering S phase.
RUNX1 accelerates tumour growth in vivo
To assess whether RUNX1 could promote tumour growth in vivo, p53-null MEFs transduced with constitutive RUNX1 or Puro control were injected subcutaneously into nude mice. Although all animals developed tumours, it was found that tumour growths arising from RUNX1 transplanted cells grew more rapidly and were significantly larger at 70 days postinjection (Po0.025, Figure 6a ). Interestingly, while there was no difference in the time taken for tumour nodules to first appear in mice receiving RUNX1 or Puro-control MEFs, the rate of tumour progression thereafter was significantly faster in the cohort transplanted with RUNX1 cells (Po0.03, Figure 6b ). RNA analysis of the excised tumours by Northern blotting . The experiment was conducted in triplicate, in the presence and absence of 4-OHT and viable cell counts were taken at day 14. The higher cell density achieved by the RUNX1-ER cells after induction with 4-OHT was confirmed but was completely abolished by co-culture with the Puro-control cells (Figure 6c ), suggesting that there was a selective advantage associated with the retention of RUNX1 expression. These results indicate that the ability of RUNX1 to enhance the growth characteristics of p53 MEFs was not restricted to monolayer cultures in vitro.
RUNX1 delays the effects of TGFb on p53-null MEF cell growth
TGFb is known to have antiproliferative and apoptotic effects in many cell types including epithelial and haematopoietic cells and is considered to be a tumour suppressor in the early stages of oncogenesis (Siegel and Massague, 2003) . Interestingly, however, TGFb can also act as a tumour progression factor, facilitating an epithelial to mesenchymal transdifferentiation of tumour cells and a more invasive, metastatic phenotype (Roberts and Wakefield, 2003) . In primary MEFs, TGFb has recently been shown to be a p53-dependent growth inhibitor (Cordenonsi et al., 2003) . RUNX1 also inhibits growth in wild-type MEFs, and RUNX family members have been implicated in TGFb responses, as target genes (Bae et al., 2001; Lee et al., 2000) , transcriptional regulators of TGFb type I receptor gene expression (Ji et al., 1998) and as co-factors of TGFb-induced Smad signalling (Hanai et al., 1999; Lee et al., 2000; Zhang et al., 2000; Ito and Miyazono, 2003) .
In this study, TGFb treatment of p53-null MEFs carrying the empty control vector resulted in significantly increased (Po0.01) cell numbers after 72 h of treatment, demonstrating that loss of p53 uncovers latent growth-promoting properties of TGFb in these cells (Figure 7) . The increased growth was accompanied by a change in morphology from cells with an epitheliallike appearance to a characteristically fibroblastic form with elongated spindle-shaped cells. Surprisingly, the ability of TGFb to confer a growth advantage was significantly delayed in the presence of RUNX1 or RUNX1-ER (Figure 7) . Furthermore, the effect was seen in both 4-OHT-treated and untreated RUNX1-ER p53-null MEFs, suggesting that both the induced and The rate of tumour growth, as measured by the time from tumour presentation to predetermined end point, was significantly faster in those animals transplanted with the RUNX1-transduced MEFs, suggesting that in vivo tumour growth is accelerated by the presence of RUNX1. (c) Northern blot analysis of 20 mg total RNA was performed using a RUNX1 exon 5-specific probe and GAPDH to control for loading. The blot was hybridized with the RUNX1 probe, stripped and reprobed with GAPDH. A single transcript of 4.4 kb was detected with the RUNX1 probe. Tracks R1-R4 are samples from tumours arising in mice injected with RUNX1 MEFs; P1 and P2 are from tumours arising in mice injected with Puro-control MEFs RUNX1 transforms p53-null MEFs SF Wotton et al uninduced forms are capable of interfering with TGFbinduced proliferation and morphological shift. Confocal microscopy using phalloidin staining of the cytoskeleton was used to study the morphological changes in more detail in two independent clones, AE4 and AE2, (data not shown). TGFb induced a rapid and dramatic increase in actin stress fibre formation arranged along the largest cell axis (Figure 8b ). The pattern was delayed by expression of RUNX1 in both 4-OHT-treated and untreated cells with very few parallel arrays staining within the first 72 h and stress fibres concentrating to sites of attachment (Figure 8f, h) . At later time points, RUNX1-expressing cells were indistinguishable from TGFb-treated Puro-control cells (data not shown). In the absence of TGFb, RUNX1 expression was associated with an epithelial-like morphology and cytoskeletal changes indicative of early transformation ( Figure  8e, g ). Densely staining cortical actin rings and an overall loss of actin stress fibres were restricted to 4-OHT-treated cells, suggesting a requirement for transcriptionally active RUNX1. These data indicate that the oncogenic effects of RUNX1 and TGFb are nonredundant and nonadditive in primary MEFs.
Discussion
In this study, we have established that when expressed in p53-null embryonic fibroblasts, RUNX1 shares many features associated with classical oncogene activity, inducing a stable transformed phenotype in vitro and accelerating tumour expansion in vivo. The continued growth of cells following confluence, together with the capacity to form transformed foci indicates that RUNX1 desensitizes cells to contact inhibition. However, this effect is masked by the presence of an intact p53 pathway, as Runx modulation in wild-type MEFs was found to lead to a senescence-like growth arrest. These observations shed light on previous conflicting (Kurokawa et al., 1996; Frank et al., 1999) .
The ability of RUNX1 to induce a senescence-like growth arrest in primary MEFs is in accord with a previous study which showed that ectopic RUNX1 induces p19 ARF , and hence acts as an agonist of p53-mediated growth arrest (Linggi et al., 2002) . Surprisingly, we observed a similar phenotypic response in cells expressing a RUNX1-ER construct in the presence or absence of inducer, and in cells expressing a RUNX1 runt homology domain linked to strong repressor domain (KRAB-RUNX1-ER). Moreover, although p19 ARF was readily detected in our MEF culture, there was no significant correlation with the growth arrest phenotype. As genetic evidence indicates that p19 ARF (Linggi et al., 2002) and p53 (this study) are required for Runx-induced senescence, our results suggest that the components of this pathway may be necessary but not sufficient for the growth arrest phenomenon.
The growth stimulatory effects of RUNX1 were revealed in the absence of p53 and appeared to be dependent on the transactivation potential of RUNX1, as these effects were seen only with RUNX1 or with RUNX1-ER in the presence of inducer, and a contrasting growth inhibition was observed with the KRAB-RUNX1-ER construct. The lack of any proliferative advantage during the growth phase and the delay in S-phase entry following mitogenic stimulation suggests that RUNX1 is not exerting a direct positive effect on the cell cycle but rather is overriding the negative growth regulatory signals that prevail at high cell density. The potential relevance to tumorigenicity is illustrated by the accelerated development of tumour nodules arising from RUNX1-expressing cells in vivo. There are intriguing parallels between the growth characteristics of RUNX1 cells in vitro and in vivo. RUNX1 cells show no growth advantage during the exponential phase of culture or early stages of tumour development in vivo. Thereafter, however, tumours arising from RUNX1-expressing cells increase in mass significantly faster than control tumours. This pattern of growth may reflect the ability of RUNX1 to counteract contact inhibition or growthlimiting conditions in a three-dimensional context. Alternatively, it is possible that RUNX1-induced tumour growth may only be manifested when the tumour cells are isolated from contact with normal cells. The ability of nontransformed cells to impose growth restrictions and prevent focus formation in neoplastic cells is a well-described phenomenon (Sakamoto et al., 1999; Chow and Rubin, 2000a, b) and has led to the hypothesis that clonal isolation can itself enhance tumour progression. The capacity of control cells to inhibit RUNX1-induced high-density growth and transformation may reflect the ability of normal stroma to restrict the growth of these cells at early stages of tumour development.
The growth promoting effects of RUNX1 in p53-null MEFs provide a parallel with previous observations of synergy between ectopic Runx2 and p53 loss in lymphomagenesis in vivo . However, the effects of RUNX1 in MEFs are not precisely analogous to those seen previously in haemopoietic cell lines, where RUNX1-ER was found to positively regulate proliferation by accelerating entry to S phase or shortening the G1 phase (Lou et al., 2000; Strom et al., 2000; Bernardin and Friedman, 2002) . In contrast, we found that RUNX1 actually slowed cell cycle progression and proliferation in primary MEFs following mitogenic stimulation. This differential response may reflect lineage-specific differences in Runx cofactors or transcriptional potential, but could also be due to secondary oncogenic mutations acquired by established haemopoietic cell lines. Nevertheless, the data presented here indicates that RUNX1 harbours oncogenic properties that may have relevance for both the haemopoietic and nonhaemopoietic tissues. The preferential activation of Myc in lymphomas of Runx2 transgenic mice ) and the activation of Runx in CD2-MYC/p53-null lymphomas (Baxter et al., 2001) suggest that complementing events in addition to inactivation of the p53 pathway are required to release the full malignant potential of the Runx genes. This hypothesis may be tested experimentally by targeting RUNX1 overexpression to a wider range of tissues, both in the presence and absence of the p53 tumour suppressor.
The relationship of TGFb to the RUNX genes stimulated our interest, as the 'two-faced' role of TGFb in early and late stages of oncogenesis present a compelling analogy to the dualistic function of the Runx genes as oncogenes or tumour suppressor genes. Moreover, TGFb/BMP signalling is intimately linked to the action of RUNX family members (Ito and Miyazono, 2003) . For example, the downstream mediators of TGFb signalling, the R-Smads can directly interact with RUNX proteins, synergistically regulate target genes and display nuclear colocalization. A further parallel emerged recently with the observation that functional p53 is required for TGFb-mediated growth arrest in primary MEFs (Cordenonsi et al., 2003) . Our results confirm and extend this observation, as we demonstrated that TGFb actually accelerates proliferation of MEFs lacking p53, as well as inducing a pronounced fibroblastic morphology accompanied by characteristic changes in the actin organization. Similar changes in the actin cytoskeleton have been described in many immortalized or transformed cell lines of epithelial or fibroblastic origin after TGFb treatment and are thought to correlate with the epithelial-mesenchymal transition that occurs in vivo in the presence of elevated levels of TGFb (Derynck et al., 2001) .
Previous studies that addressed functional cooperation have suggested that coexpression of Runx2 can sensitize cells to the growth inhibitory effects of TGFb/ BMP signalling (Vaillant et al., 1999) and that RUNX1-ETO can inactivate TGFb/Smad function (Jakubowiak et al., 2000) . However, in the p53-null MEFs, RUNX1 did not augment the growth promoting effects of TGFb and delayed the characteristic morphological response. Although cells transformed by the induced RUNX1-ER retained an epithelial-like morphology and cytoskeletal changes indicative of early oncogenesis, these effects in themselves were not responsible for the delay in response to TGFb since this was also observed with the uninduced RUNX1-ER. This suggests that transcriptional activity of RUNX1 is not required although the involvement of signalling through the Smad pathway remains a possibility. One possible explanation for our results may be that RUNX1 is sequestering SMADs away from target genes mediating the TGFb-specific effects. Interestingly, an analogous phenotype to that observed in RUNX1 cells has also been seen with inducible Ha-ras and, moreover, similar cytoskeletal changes were observed when these cells were treated with TFGb (Moustakas and Stournaras, 1999) .
Clearly, RUNX1 and TGFb can both act as either tumour suppressors or promoters depending on the cellular context or stage of tumorigenesis and further studies will address how these pathways interact and the significance for oncogenesis.
Materials and methods
Cells and constructs
MEFs were prepared from 13.5 day embryos of wild-type (C57Bl6/CBA) or p53-null mice (Donehower et al., 1992) . The head and red organs were removed and the body minced and treated with 0.5% trypsin for 15 min to disperse the cells. The cells were grown in culture for three population doublings and then frozen stocks were made. The virus packaging line Phoenix (ecotropic) was obtained from G Nolan, Stanford University, Palo Alto, CA, USA. All cultures were maintained in DMEM (Invitrogen) plus 10% fetal calf serum (FCS), glutamine (2 mM) and penicillin/streptomycin (200 U/ml/ 100 mg/ml) unless otherwise stated. The retroviral vectors used were all based on the pBabe plasmid (Morgenstern and Land, 1990) , carrying the puromycin selectable marker, into which the different constructs were inserted. The RUNX1 (pBabe-AML), RUNX1-ER (pBabe-AML-ER) and KRAB-RUNX1-ER (pBabe-KRAB-AML-ER) have been previously described (Lou et al., 2000) . The vector control was the pBabe-Puro plasmid with no insertion. Single-cell cloning was achieved by plating at low cell density then using cloning rings (Sigma) and trypsin to remove the cells for expansion.
Retroviral transduction
Phoenix cells were plated at 5 Â 10 6 in 10 cm dishes and incubated overnight at 371C. Transfections were carried out using Superfect Transfection Reagent (Qiagen) according to the manufacturer's protocol for transient transfection of adherent cells. Viral supernatants were harvested after 48 h incubation at 371C, filtered through 0.45 mm filters (Sartorius), quick frozen and maintained at À801C until required. Second viral supernatants were harvested after a further 24 h and treated similarly. MEFs were plated at 8 Â 10 5 in 10 cm dishes and incubated overnight before infection with viral supernatants supplemented with 4 mg/ml polybrene (Sigma). Infections were carried out by the replacement of culture medium with the appropriate first harvested viral supernatant and incubation overnight at 371C followed by incubation with the second harvested viral supernatant for a further 8 h. Infected MEFs were then incubated overnight in normal medium after which selection was applied using puromycin (Sigma) at 2 mg/ ml for 4 days. Control uninfected MEFs all died under these selection conditions. Following selection, transduced MEFs were removed from the plates, counted and used in the various experimental procedures.
Growth curves
Transduced MEFs were plated at 2.5 Â 10 4 /well in 12-well plates or 1 Â 10 5 /well in six-well plates and incubated in selection medium containing 2 mg/ml puromycin. ER constructs were induced in the presence of 4-OHT (Sigma). 4-OHT dissolved in ethanol (0.1 mM) was added to cells at a final concentration of 200 nM. Equivalent volumes of ethanol were added to control cultures (described as untreated in text). Live cell counts were carried out using a haemocytometer using trypan blue as a vital indicator. Media changes were carried out every 3-4 days. Graphs were plotted using Sigma plot and significance values determined by Student's t-test. Unless otherwise stated, error bars relate to standard deviations. Postconfluent cultures were maintained in 25 cm 2 flasks without passage. SA-b-gal activity was detected using a solution of X-gal (Invitrogen) at pH 6.0 by the modified method described previously (Serrano et al., 1997) .
Cell cycle analysis
MEFs in log phase of growth were synchronized by culturing for 48 h in 0.2% serum. Cells were then sampled for flow cytometry analysis at 6 h intervals following return to normal growth conditions (10% serum). Protocol for cell cycle analysis has been described previously (Blyth et al., 2000) . Briefly, 10 5 -10 6 cells were harvested, centrifuged and washed three times in phosphate-buffered saline (PBS) containing 1 mg/ml glucose. Following washing, cells were centrifuged, the pellet vigorously vortexed before adding ice-cold 70% ethanol in a drop-wise manner. Cells were fixed for a minimum of 18 h at 41C. For staining, cells were centrifuged and resuspended by gentle vortex in propidium iodide (PI) staining solution (50 mg/ml PI and 10 U/ml RNase A (Sigma) in PBS buffer containing 1 mg/ml glucose). Samples were incubated at room temperature on a rocking platform for at least 30 min and analysed on a Beckman-Coulter Epics XL within 6 h. Analysis was performed using EXPO32 software package.
Western blotting and antibodies
Cells were washed in cold PBS and whole-cell extracts were prepared by lysing the cells in lysis buffer (20 mM HEPES, 5 mM EDTA, 10 mM EGTA, 5 mM NaF, 0.1 mg/ml okadaic acid, 10% glycerol, 1 mM DTT containing 0.4 M KCl, 0.4% Triton X-100 and protease inhibitors; 5 mg/ml leupeptin, 5 mg/ ml aprotinin, 5 mg/ml pepstatin A, 1 mM benzamidine, 50 mg/m PMSF). Samples equivalent to 10 mg total protein (Biorad protein assay) were resolved on 8 or 17% SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore). Membranes were probed with antibodies to: ERa -sc542 (Santa Cruz Biotechnology); p19 ARF -R562 (Abcam); p16 (M156) sc1207; b-actin -(I-19) sc1616 (Santa Cruz Biotechnology). Western blots were developed with ECL (Amersham) according to the manufacturer's protocol.
Co-culture system
Equal numbers of cells (1 Â 10 4 ) from an individual RUNX1-ER clone and an individual Puro-control clone were plated together in a single well of a 12-well plate (total cell number ¼ 2 Â 10 4 ). Cell numbers at the start were controlled for by plating RUNX1-ER cells alone at 1 Â 10 4 and 2 Â 10 4 and Puro-control cells alone at 1 Â 10 4 and 2 Â 10 4 . Seeded wells were treated with either ethanol or tamoxifen and the experiment carried out in triplicate. Various combinations of different clones were used and viable cell counts were recorded after 14 days.
In vivo transplantation studies p53-null MEFs were transduced with either the constitutive RUNX1 construct or Puro-vector control. After 8 days of in vitro selection, 10 6 cells in 0.2 ml PBS were injected subcutaneously into the left flank of MFI-Nude mice (Harlan-Olac, UK). Six MFI-nudes received RUNX1-transduced p53-null MEFs and five received Puro-vector control cells. Animals were housed in sterile filter-top cages, monitored thrice weekly and killed when tumour masses reached a predetermined size (17 mm diameter) or became ulcerated, in line with the UK Animal Procedures Act Project License.
Northern Blot hybridization
A measure of 20 mg of mouse total RNA was separated on a 1% agarose gel containing 2.2 M formaldehyde, stained with ethidium bromide to assess quality and quantity of RNA, and transferred onto Hybond N membrane (Amersham Pharmacia Biotech) in 10 Â SSC. Filters were hybridized in RapidHyb buffer (Amersham Pharmacia Biotech) at 651C for 120 min. Blots were washed at high stringency (3 Â 20 min washes in 0.1x SSC, 0.5% SDS at 601C) and exposed to Kodak film at À701C.
TGFb treatment and direct fluorescence of the actin cytoskeleton RUNX1-ER-transduced or Puro-control cells were plated at 1 Â 10 5 /well in six-well plates and allowed to adhere for 16 h after which time ethanol or 4-OHT (200 nM) and TGFb (5 ng/ ml) were added. Live cell counts and analyses were conducted as described above at day 4 after plating.
Cells were prepared for direct fluorescence of the actin skeleton: RUNX1-ER (AE) or Puro-vector control (PE) MEF clones (2 Â 10 4 /well) were grown to 80% confluence on poly-Llysine-coated (13.3 mg/ml) glass chamber slides and then treated with (200 nM) tamoxifen and/or 5 ng/ml TGFb for 72 h. The cells were fixed in 3.3% paraformaldehyde, immersed in 20 mM glycine for 5 min to remove free aldehyde groups and permeabilized with 0.1% Triton/PBS for 10 min 3 Â . Between each treatment, the cells were washed 3 Â in PBS. The cells were blocked in 0.1% Triton/10% FCS/PBS for 1 h, washed 2 Â in 0.1% Triton/PBS and incubated with 1 mg/ml TRITCconjugated phalloidin (Sigma p1951) for 30 min at room temperature. The slides were washed 3 Â in PBS, mounted and fluorescent images captured using a confocal microscope (Leica SP-2).
